How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study

K. re I. Birkeland, Johan Bodegard, Anna Norhammar, Josephina G. Kuiper, Elena Georgiado, Wendy L. Beekman-Hendriks, Marcus Thuresson, Marc Pignot, Ron M. C. Herings, Adriaan Kooy

Research output: Contribution to journalArticleAcademicpeer-review

58 Citations (Scopus)

Abstract

Aims: Enrollment criteria vary substantially among cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter-2 inhibitors (SGLT-2is), which impacts the relationship between a trial population and the general type 2 diabetes (T2D) population. The aim of this study was to evaluate the representativeness of four SGLT-2i CVOTs of a general T2D population. Methods: T2D patients from Germany, The Netherlands, Norway and Sweden were included in the study. Given the available data per country, key inclusion and exclusion criteria were defined by diagnoses, procedures and drug treatments to facilitate comparability among countries. Representativeness was determined by dividing the number of patients fulfilling the key enrolment criteria of each CVOT (CANVAS, DECLARE-TIMI 58, EMPA-REG OUTCOME, VERTIS-CV) by the total T2D population. Results: In 2015, a total T2D population of 803 836 patients was identified in Germany (n = 239 485), in The Netherlands (n = 36 213), in Norway (n = 149 782) and in Sweden (n = 378 356). These populations showed a 25% to 44% cardiovascular (CV) disease baseline prevalence and high CV-preventive drug use (>80%). The general T2D population had less prevalent CV disease and patients were slightly older than those included in the CVOTs. The DECLARE-TIMI 58 trial had the highest representativeness, 59% compared to the general T2D population, and this representativeness was almost 2-, 3- and 4-fold higher compared to the CANVAS (34%), EMPA-REG OUTCOME (21%) and VERTIS-CV (17%) trials, respectively. Conclusions: In large T2D populations within Europe, consistent patterns of representativeness of CVOTs were found when applying the main enrolment criteria. The DECLARE-TMI 58 trial had the highest representativeness, indicating that it included and examined patients who are most representative of the general T2D patients in the studied countries.
Original languageEnglish
Pages (from-to)968-974
Number of pages7
JournalDiabetes, Obesity and Metabolism
Volume21
Issue number4
Early online date2019
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • Aged Aged, 80 and over Cardiovascular Diseases/complications/drug therapy/*prevention & control *Clinical Trials as Topic Diabetes Mellitus, Type 2/complications/*drug therapy Female Germany Humans Male Middle Aged Netherlands Norway *Patient Selection Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use Sweden *SGLT2 inhibitors *cardiovascular disease *cardiovascular outcome trial *observational study *representativeness

Cite this